Artielle ImmunoTherapeutics Company
Artielle ImmunoTherapeutics develops recombinant T-cell receptor ligands to treat T-cell-mediated inflammatory diseases.
Technology:
Cell-based gene therapy, Medical Devices
Industry:
PharmTech, Private
Headquarters:
San Mateo, California, United States
Zip:
1-10
Founded Date:
2004-01-01
Employees Number:
1-10
Funding Status:
Early Stage Venture
Acquisitions Number:
4
Investors Number:
4
Total Funding:
11185740
Estimated Revenue:
$1M to $10M
Last Funding Date:
2010-04-13
Last Funding Type:
Convertible Note
Register and Claim Ownership